TerminatedNCT00977522

PF-03463275 for schizophrenia

Medication studyAges 18–55United States

The study in practice

Understand this study

Listed age limits: 18 years to 55 years.

Listed locations: Cerritos and 36 more locationsSee all locations and recruitment
Study phase: Phase 2

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateNovember 2009

Recruitment status: Terminated
Enrollment listed in the registry: 207
Sponsor: Pfizer
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States
Age range: From 18 Years to 55 Years
Official registry ID: NCT00977522
Official title: Show the full official title
A Randomized Phase 2, Double-Blind, Placebo-Controlled, Multi-Center Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia Treated With A Stable Dose Of A Second Generation Antipsychotic

Terminated

Cerritos · Chula Vista · Escondido

26 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Pfizer.

Does this study involve medication?

Yes. The study involves medication, including PF-03463275 and Placebo.

Who can participate?

Listed age limits: 18 years to 55 years.

Is this study still recruiting?

The registry lists this study as terminated.